Researchers from the University of Aberdeen (UK) have developed a new drug that will eliminate fatty deposits inside the arteries. results published In Journal of Translational Medicine (JTM).
A new drug based on trodusquemin reduces the activity of the PTP1B enzyme in the body. PTP1B levels are often elevated in people with obesity and diabetes, as well as in conditions involving long-term inflammation, such as sepsis, diabetic foot, and allergic pneumonia. When PTB1B levels increase in the body, a series of processes are triggered that lead white blood cells (a type of immune cell) to absorb oxidized cholesterol. Leukocytes then transform into foam cells containing low-density lipoproteins. Such altered cells can settle in the walls of the arteries and reduce their elasticity.
An experiment on laboratory mice showed that use of the new drug prevented white blood cells (leukocytes) from turning into foam cells by inhibiting PTP1B.
The researchers also found that genetic deletion of PTP1B (absence from the genome) was associated with lower levels of low-density lipoprotein (LDL) in the blood of mice. It is LDL that causes the formation of atherosclerotic plaques in the arteries.
Scientists stated that the effect of the use of the drug will most likely be similar in humans. The study authors suggested that their discovery would serve as a new therapeutic mechanism to protect against atherosclerosis, the cause of most heart attacks and strokes.
existed before named Nutritional supplements for heart healing.